Pitcairn Co. lowered its position in shares of Qiagen N.V. (NASDAQ:QGEN) by 0.2% during the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 9,304 shares of the company’s stock after selling 20 shares during the period. Pitcairn Co.’s holdings in Qiagen N.V. were worth $312,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors also recently bought and sold shares of the company. Dimensional Fund Advisors LP increased its position in Qiagen N.V. by 58.3% in the fourth quarter. Dimensional Fund Advisors LP now owns 72,909 shares of the company’s stock worth $2,043,000 after buying an additional 26,838 shares in the last quarter. Teachers Advisors LLC increased its stake in Qiagen N.V. by 4.4% in the fourth quarter. Teachers Advisors LLC now owns 238,461 shares of the company’s stock worth $6,682,000 after buying an additional 10,158 shares during the period. Capstone Asset Management Co. increased its stake in Qiagen N.V. by 6.4% in the first quarter. Capstone Asset Management Co. now owns 74,130 shares of the company’s stock worth $2,148,000 after buying an additional 4,441 shares during the period. Fox Run Management L.L.C. increased its stake in Qiagen N.V. by 53.3% in the first quarter. Fox Run Management L.L.C. now owns 15,789 shares of the company’s stock worth $457,000 after buying an additional 5,489 shares during the period. Finally, Rehmann Capital Advisory Group acquired a new stake in Qiagen N.V. during the first quarter worth about $207,000. 60.07% of the stock is owned by institutional investors.

Shares of Qiagen N.V. (QGEN) opened at 31.36 on Wednesday. The firm has a market capitalization of $7.16 billion, a price-to-earnings ratio of 95.90 and a beta of 1.14. The company’s 50 day moving average price is $33.21 and its 200 day moving average price is $31.25. Qiagen N.V. has a 52-week low of $24.86 and a 52-week high of $35.26.

Qiagen N.V. (NASDAQ:QGEN) last announced its quarterly earnings data on Thursday, July 27th. The company reported $0.30 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $0.28 by $0.02. Qiagen N.V. had a return on equity of 11.04% and a net margin of 5.44%. The company had revenue of $349 million for the quarter, compared to analyst estimates of $353.09 million. During the same quarter last year, the firm earned $0.24 EPS. Qiagen N.V.’s revenue for the quarter was up 4.4% compared to the same quarter last year. Analysts forecast that Qiagen N.V. will post $1.23 earnings per share for the current year.

WARNING: This article was originally posted by Watch List News and is the sole property of of Watch List News. If you are accessing this article on another publication, it was copied illegally and reposted in violation of US and international copyright & trademark laws. The correct version of this article can be viewed at https://www.watchlistnews.com/qiagen-n-v-qgen-shares-sold-by-pitcairn-co/1494071.html.

A number of analysts recently issued reports on QGEN shares. TheStreet downgraded shares of Qiagen N.V. from a “b-” rating to a “c” rating in a research report on Monday, April 24th. Deutsche Bank AG restated a “buy” rating on shares of Qiagen N.V. in a report on Tuesday, May 2nd. Commerzbank Ag restated a “buy” rating on shares of Qiagen N.V. in a report on Friday, June 23rd. Barclays PLC restated a “buy” rating and issued a $33.00 price target on shares of Qiagen N.V. in a report on Monday, May 15th. Finally, Morgan Stanley restated an “overweight” rating and issued a $37.00 price target (up previously from $36.00) on shares of Qiagen N.V. in a report on Monday, July 10th. Nine analysts have rated the stock with a hold rating and five have given a buy rating to the stock. Qiagen N.V. presently has a consensus rating of “Hold” and a consensus target price of $33.17.

Qiagen N.V. Company Profile

QIAGEN N.V. (QIAGEN) is a holding company. The Company is engaged in providing Sample to Insight solutions that transform biological samples into molecular insights. Its Sample to Insight solutions integrate sample and assay technologies, bioinformatics and automation systems. Its sample technologies are used for isolating and preparing deoxyribonucleic acid (DNA), ribonucleic acid (RNA) and proteins from blood or other liquids, tissue, plants or other materials.

Want to see what other hedge funds are holding QGEN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Qiagen N.V. (NASDAQ:QGEN).

Institutional Ownership by Quarter for Qiagen N.V. (NASDAQ:QGEN)

Receive News & Ratings for Qiagen N.V. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Qiagen N.V. and related companies with Analyst Ratings Network's FREE daily email newsletter.